Clinical trials
Advance Solid Tumors clinical trials
Below are recruiting advance solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,390 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06410131RecruitingPhase 1
Safety study of FTL008.16 for advanced solid tumors
This trial tests an investigational drug called FTL008.16 for people with advanced solid tumors that may carry a protein called 5T4. The main goal is to see if the drug is safe and tolerable.
Beijing, Beijing MunicipalityAges 18–75 - NCT07142980RecruitingPhase 1
Study of HRS-7172 for advanced solid tumors with RAS mutations
This trial tests a new drug, HRS-7172, for people with advanced solid tumors that have RAS mutations or amplifications. It aims to see if the drug is safe and effective for these cancers.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07134998RecruitingPhase 1
Study of HRS-6093 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05772455RecruitingPhase 1
Drug study for adults with solid tumors
This Phase 1 study tests XZB-0004 in adults with solid cancers to check safety and how the body responds to the drug. It may help doctors learn whether this treatment could be useful for certain tumor types, including non-small cell lung cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06504368RecruitingPhase 1
Testing a new drug DCR-PDL1 for advanced solid tumors
This trial tests an experimental drug called DCR-PDL1 for people with advanced solid tumors or non-Hodgkin's lymphoma that has not responded to, progressed on, or could not tolerate standard treatments, or for which no standard treatment exists. The goal is to see if it is safe and how the body processes it.
Irving, TexasAges 18 years+ - NCT07589530RecruitingPhase 1/Phase 2
CAR NK Cell Therapy for Advanced Solid Tumors
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07712029RecruitingPhase 2
A new drug combo for EGFR positive advanced solid tumors
This trial tests a new combination of two drugs—Becotatug Vedotin (a targeted therapy that delivers chemotherapy directly to EGFR-positive cancer cells) and Pucotenlimab (an immunotherapy that helps your immune system fight cancer). It is for people with advanced solid tumors that have not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07290088RecruitingPhase 2/Phase 3
Testing a new drug for advanced solid tumors
This trial tests a new drug called PRL3-zumab for people with advanced solid tumors (cancers that have spread). The goal is to see if it can shrink tumors or slow their growth. It is an option for patients who have had limited prior treatments.
Kota BharuAges 18–75 - NCT07027488RecruitingPhase 1
Testing AB821 for advanced solid tumors that resist immunotherapy
This trial tests a new study drug, AB821, for people with advanced solid tumors that have stopped responding to standard treatments, especially immunotherapy. The goal is to see if AB821 can shrink tumors or slow their growth.
New Haven, ConnecticutAges 18 years+ - NCT06763159RecruitingPhase 1
Study of HS-20124 for advanced solid tumors
This study tests a new drug called HS-20124 for people with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05693844RecruitingPhase 1/Phase 2
MSLN CAR T cell therapy for advanced solid tumors
This early-phase study tests a lab-made immune cell therapy (CAR T cells) that targets a protein called mesothelin (MSLN) in advanced or metastatic solid cancers. It may help your body better recognize and attack tumor cells, especially if standard first treatments did not work or are not available.
Beijing, Beijing MunicipalityAges 18–75 - NCT06463340RecruitingPhase 1
Study of SGR-3515 for advanced solid tumors
This trial tests a new drug called SGR-3515 for people with advanced solid tumors. It aims to see if the drug is safe and how it works in the body.
New Haven, ConnecticutAges 18 years+ - NCT06656390RecruitingPhase 1/Phase 2
Testing ALK201 for advanced solid tumors
This trial tests a new drug, ALK201, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
Denver, ColoradoAges 18–75 - NCT06258304RecruitingPhase 1
Testing a new immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug, GIGA-564, for people with advanced solid tumors that have not responded to or have returned after standard treatments. The goal is to see if the drug is safe and effective, and to find the best dose.
Bethesda, MarylandAges 18 years+ - NCT06158477RecruitingPhase 1
A study of JYP0035 for advanced solid tumors
This trial tests a new drug called JYP0035 alone in people with advanced solid tumors. It aims to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–74 - NCT05970016RecruitingPhase 1/Phase 2
Study for advanced solid cancers with a DNA repair target
This Phase I/II trial tests an investigational treatment in people with advanced solid tumors that have grown despite standard therapy, or where standard options aren’t available. In later Phase II, the trial mainly enrolls patients whose tumor shows a specific DNA repair problem (DDR defect).
Beijing, Beijing MunicipalityAges 18–70 - NCT06265727RecruitingPhase 1/Phase 2
Study of CRB-701 for solid tumors with nectin-4
This trial tests a new drug, CRB-701, for people with advanced solid tumors that have a protein called nectin-4 on their surface. It might be an option if other treatments have stopped working or are not available.
Birmingham, AlabamaAges 18 years+ - NCT07004296RecruitingPhase 1
Study of HDM2005 for advanced solid tumors
This trial tests a new drug, HDM2005, in people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective for tumors that show a specific marker called ROR1.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07480733RecruitingPhase 2
Study of two drugs for advanced solid tumors
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07228247RecruitingPhase 1/Phase 2
Study of HMPL-A251 for advanced HER2-positive cancers
This study tests an experimental drug (HMPL-A251) for people with advanced solid tumors that have the HER2 protein. It aims to see if the drug can shrink tumors or slow their growth.
Denver, ColoradoAges 18 years+ - NCT06682117Recruiting
A study of a personalized vaccine for advanced solid tumors
This trial tests a personalized vaccine made from your own cells to help your immune system attack tumor-specific targets. It may be an option if standard treatments have stopped working or caused side effects you can't tolerate.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06248697RecruitingEarly Phase 1
CAR-T cells targeting MSLN with PD-1/CTLA-4 blockers for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-T cells) that target a protein called MSLN on cancer cells, and also release a special antibody to block two other proteins (PD-1 and CTLA-4) that cancers use to hide from the immune system. It is for people with advanced solid tumors like non-small-cell lung cancer or mesothelioma who have not responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06248411RecruitingPhase 1
Study of KK2260 for advanced solid tumors
This study tests a new experimental drug, KK2260, for people with advanced or advanced solid tumors, especially esophageal cancer and certain head and neck cancers. The goal is to see if the drug is safe and helps shrink or control the cancer.
Nagoya, Aichi-kenAges 18 years+ - NCT06474455RecruitingPhase 1/Phase 2
Study of SHR-9839 with other treatments for advanced solid tumors
This trial tests a new drug called SHR-9839 combined with other cancer treatments for people with advanced solid tumors, including a certain type of lung cancer. The goal is to see if the combination is safe and effective against the cancer.
Zhengzhou, HenanAges 18–75
Hear when a new Advance Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advance solid tumors?
- Yes. Clin2 currently lists 1,390 recruiting advance solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advance solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advance solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.